FRAMINGHAM, MA — SCIEX, a global leader in
life science analytical technologies, launches the Echo® MS+ system at SLAS
2024. The system couples proprietary Acoustic Ejection Mass Spectrometry
technology and Open Port Interface (OPI) sampling with the capabilities of either
the SCIEX ZenoTOF 7600 or Triple Quad 6500+ system to deliver precise
qualitative and quantitative results, through an expanded panel of robust
high-throughput screening workflows. The system addresses key challenges in
high-throughput screening applications for drug discovery without the need for
extensive method development. This is achieved through the introduction of new,
flexible workflows for small and large molecules that leverage the capabilities
of high-resolution mass spectrometry for improved selectivity and sensitivity
compared to other analytical tools. Through a combination of high speed of
analysis, high data quality and minimal sample and reagent consumption, the system
has the potential to reduce the time, cost, and risk in making critical
decisions during the early phases of the drug development pipeline. With this
expanded capability, researchers in drug discovery will have the ability to
make faster and more confident decisions in hit identification and iterative
lead optimization. This will help speed up the process of drug discovery and
reduce the potential for false positive or false negative results. “Building on the speed and fidelity of results
that this technology can deliver by integrating it with high resolution mass
spectrometry is going to enable us to develop new and novel workflows across a
range of molecule types for high-throughput screening applications,” said Jose
Castro-Perez, vice president of product management at SCIEX. “Moving forward we
intend to develop further new and novel workflows for the Echo® MS+ system in
collaboration with customers at our global Echo® MS Center of Excellence. The
goal is to address key unmet analytical needs with this disruptive
technology.”